Luvesilocin


Luvesilocin, also known as RE104 and FT-104, as well as 4-glutaryloxy-N,''N''-diisopropyltryptamine, is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families which is under development for the treatment of psychiatric disorders. It is taken orally or by subcutaneous injection.
The drug is a prodrug ester of 4-HO-DiPT, which acts as a non-selective serotonin receptor agonist including of the serotonin 5-HT2A receptor. 4-HO-DiPT produces psychedelic-like effects in animals.
Luvesilocin was first described in the literature in 2021. It is under development for the treatment of postpartum depression and treatment-resistant depression. As of September 2025, the drug has reached phase 2 clinical trials. A phase 3 trial is planned for 2026.

Use and effects

The effects of luvesilocin have been clinically studied. It was evaluated at doses of 5 to 40mg by subcutaneous injection in this study. The drug was specifically assessed in terms of modified Drug Effects Questionnaire ratings, Mystical Experience Questionnaire ratings, and adverse effects. The mean duration of the psychedelic experience after administration of luvesilocin at a dose of 30mg was found to be 3.6hours.

Interactions

Pharmacology

Pharmacodynamics

Luvesilocin is a prodrug that is metabolized into 4-HO-DiPT. This metabolite is an analogue of the neurotransmitter serotonin and acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor. Activation of the serotonin 5-HT2A receptor is thought to be specifically responsible for the hallucinogenic effects of serotonergic psychedelics.
4-HO-DiPT produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. In drug discrimination tests, 4-HO-DiPT fully substituted for the psychedelic drug DOM, with 5-fold lower potency than DOM and 2-fold lower potency than psilocin.
The drug activates basolateral amygdala interneurons via the serotonin 5-HT2A receptor to enhance GABAergic inhibition of principal neurons in the BLA, which may mediate an anxiolytic effect of suppression of learned fear in rodents.

Pharmacokinetics

Given by subcutaneous injection, the elimination half-life of luvesilocin is 0.43 to 0.64hours and of 4-HO-DiPT is 2.7 to 4.1hours. The mean duration with this route at the employed dose was 3.6hours.

Chemistry

Synthesis

The chemical synthesis of luvesilocin has been described.

Analogues

s of luvesilocin include 4-HO-DiPT, 4-AcO-DiPT, 4-PrO-DiPT, 4-AcO-DMT, 4-PrO-DMT, and 4-GO-DMT, among others.

History

Luvesilocin was first described in the literature in 2021.

Society and culture

Names

Luvesilocin is the generic name of the drug and its. It is also known by its developmental code names RE104 or RE-104 and FT104 or FT-104.

Legal status

Canada

Luvesilocin is not a controlled substance in Canada as of 2025.

United States

Luvesilocin is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

Research

Luvesilocin is under development for the treatment of postpartum depression, treatment-resistant depression, and other psychiatric disorders. As of September 2025, it has reached phase 2 clinical trials for these indications. A phase 3 trial is planned for 2026. The drug is being developed by Reunion Neuroscience.